Den europeiske union - norsk - EMA (European Medicines Agency)

pacira limited - cytarabin - meningeal neoplasmer - antineoplastiske midler - intratekal behandling av lymfomatøs meningitt. i de fleste pasienter vil slike behandling være en del av symptomatisk palliation av sykdommen.

Norge - norsk - Statens legemiddelverk

2care4 aps - ibandronatnatriummonohydrat - injeksjonsvæske, oppløsning - 3 mg

Norge - norsk - Statens legemiddelverk

ethypharm (1) - adrenalintartrat - injeksjonsvæske, oppløsning - 0.1 mg/ ml

Norge - norsk - Statens legemiddelverk

elanco europe ltd - aeromonas salmonicida subspesie salmonicida, inaktivert / vibrio anguillarum serotype o1, inaktivert - injeksjonsvæske, emulsjon

Norge - norsk - Statens legemiddelverk

elanco gmbh - aeromonas salmonicida, hel, inaktivert / vibrio anguillarum, serotype o1, inaktivert / vibrio anguillarum, serotype o2a, inaktivert / aliivibrio salmonicida, inaktivert / moritella viscosa, inaktivert / pankreasnekrosevirus, infeksiøs, inaktivert - injeksjonsvæske, emulsjon

Norge - norsk - Statens legemiddelverk

atnahs pharma netherlands b.v. - ketorolaktrometamol - injeksjonsvæske, oppløsning - 30 mg/ ml

Norge - norsk - Statens legemiddelverk

ethypharm (2) - glykopyrroniumbromid - injeksjonsvæske, oppløsning - 200 mikrog/ ml

Norge - norsk - Statens legemiddelverk

ethypharm (1) - suksametoniumkloriddihydrat - injeksjons-/infusjonsvæske, oppløsning - 50 mg/ ml

Norge - norsk - Statens legemiddelverk

ethypharm (1) - adrenalintartrat - injeksjonsvæske, oppløsning - 1 mg/ ml

Den europeiske union - norsk - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - forløpercellelymfoblastisk leukemi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.